Why the study?
The COVID-19 outbreak warranted the design and development of novel anti-COVID therapeutics.
Computational modeling identified a lead optimized small molecule with high binding affinity to the GTP pocket of SARS-CoV-2 RdRp, providing a candidate for COVID-19 drug development.
The current COVID-19 outbreak warrants the design and development of novel anti-COVID therapeutics. Using a combination of bioinformatics and computational tools, we modelled the 3D structure of the RdRp (RNA-dependent RNA polymerase) of SARS-CoV2 (severe acute respiratory syndrome coronavirus-2) and predicted its probable GTP binding pocket in the active site. GTP is crucial for the formation of the initiation complex during RNA replication. This site was computationally targeted using a number of small molecule inhibitors of the hepatitis C RNA polymerase reported previously. Further optimizations suggested a lead molecule that may prove fruitful in the development of potent inhibitors against the RdRp of SARS-CoV2.
No takes yet. Share an insight, caveat, or question.
Ahmad et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: